vs
Alpha Cognition Inc.（ACOG）与Adaptive Biotechnologies Corp（ADPT）财务数据对比。点击上方公司名可切换其他公司
Adaptive Biotechnologies Corp的季度营收约是Alpha Cognition Inc.的25.7倍（$71.7M vs $2.8M）。Adaptive Biotechnologies Corp净利率更高（-18.9% vs -245.5%，领先226.5%）。Adaptive Biotechnologies Corp自由现金流更多（$1.4M vs $-7.1M）
ExpreS2ion Biotechnologies是一家丹麦生物技术企业，总部位于丹麦霍尔斯霍姆，专注于新型疫苗和免疫疗法产品的研发，在纳斯达克第一北增长市场瑞典板块挂牌上市。
ACOG vs ADPT — 直观对比
营收规模更大
ADPT
是对方的25.7倍
$2.8M
净利率更高
ADPT
高出226.5%
-245.5%
自由现金流更多
ADPT
多$8.5M
$-7.1M
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $2.8M | $71.7M |
| 净利润 | $-6.9M | $-13.6M |
| 毛利率 | — | 74.6% |
| 营业利润率 | -283.7% | -17.8% |
| 净利率 | -245.5% | -18.9% |
| 营收同比 | — | 51.0% |
| 净利润同比 | — | 59.7% |
| 每股收益（稀释后） | $-0.10 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACOGADPT
| Q4 25 | $2.8M | $71.7M | ||
| Q3 25 | $2.8M | $94.0M | ||
| Q2 25 | $1.7M | $58.9M | ||
| Q1 25 | $2.9M | $52.4M | ||
| Q4 24 | — | $47.5M | ||
| Q3 24 | — | $46.4M | ||
| Q2 24 | — | $43.2M | ||
| Q1 24 | — | $41.9M |
净利润ACOGADPT
| Q4 25 | $-6.9M | $-13.6M | ||
| Q3 25 | $-1.3M | $9.5M | ||
| Q2 25 | $-10.5M | $-25.6M | ||
| Q1 25 | $-2.0M | $-29.9M | ||
| Q4 24 | — | $-33.7M | ||
| Q3 24 | — | $-32.1M | ||
| Q2 24 | — | $-46.2M | ||
| Q1 24 | — | $-47.5M |
毛利率ACOGADPT
| Q4 25 | — | 74.6% | ||
| Q3 25 | — | 80.7% | ||
| Q2 25 | 96.7% | 69.4% | ||
| Q1 25 | 99.6% | 67.6% | ||
| Q4 24 | — | 62.0% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 55.3% | ||
| Q1 24 | — | 56.9% |
营业利润率ACOGADPT
| Q4 25 | -283.7% | -17.8% | ||
| Q3 25 | -187.0% | 10.9% | ||
| Q2 25 | -346.1% | -42.5% | ||
| Q1 25 | -125.9% | -56.4% | ||
| Q4 24 | — | -71.3% | ||
| Q3 24 | — | -70.3% | ||
| Q2 24 | — | -109.6% | ||
| Q1 24 | — | -116.5% |
净利率ACOGADPT
| Q4 25 | -245.5% | -18.9% | ||
| Q3 25 | -46.4% | 10.2% | ||
| Q2 25 | -632.7% | -43.5% | ||
| Q1 25 | -68.5% | -56.9% | ||
| Q4 24 | — | -71.0% | ||
| Q3 24 | — | -69.1% | ||
| Q2 24 | — | -107.0% | ||
| Q1 24 | — | -113.5% |
每股收益（稀释后）ACOGADPT
| Q4 25 | $-0.10 | $-0.08 | ||
| Q3 25 | $-0.30 | $0.06 | ||
| Q2 25 | $-0.65 | $-0.17 | ||
| Q1 25 | $-0.13 | $-0.20 | ||
| Q4 24 | — | $-0.22 | ||
| Q3 24 | — | $-0.22 | ||
| Q2 24 | — | $-0.31 | ||
| Q1 24 | — | $-0.33 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $66.0M | $70.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $62.5M | $218.8M |
| 总资产 | $79.7M | $512.7M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ACOGADPT
| Q4 25 | $66.0M | $70.5M | ||
| Q3 25 | $35.4M | $55.0M | ||
| Q2 25 | $39.4M | $43.2M | ||
| Q1 25 | $45.5M | $50.6M | ||
| Q4 24 | — | $47.9M | ||
| Q3 24 | — | $38.1M | ||
| Q2 24 | — | $59.8M | ||
| Q1 24 | — | $71.2M |
股东权益ACOGADPT
| Q4 25 | $62.5M | $218.8M | ||
| Q3 25 | $33.9M | $204.4M | ||
| Q2 25 | $31.9M | $179.7M | ||
| Q1 25 | $40.8M | $190.4M | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | $223.8M | ||
| Q2 24 | — | $241.6M | ||
| Q1 24 | — | $274.9M |
总资产ACOGADPT
| Q4 25 | $79.7M | $512.7M | ||
| Q3 25 | $46.3M | $490.6M | ||
| Q2 25 | $45.1M | $496.6M | ||
| Q1 25 | $48.6M | $510.9M | ||
| Q4 24 | — | $539.4M | ||
| Q3 24 | — | $558.5M | ||
| Q2 24 | — | $584.9M | ||
| Q1 24 | — | $620.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.9M | $2.1M |
| 自由现金流经营现金流 - 资本支出 | $-7.1M | $1.4M |
| 自由现金流率自由现金流/营收 | -252.6% | 2.0% |
| 资本支出强度资本支出/营收 | 5.3% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-20.7M | $-48.9M |
8季度趋势，按日历期对齐
经营现金流ACOGADPT
| Q4 25 | $-6.9M | $2.1M | ||
| Q3 25 | $-5.3M | $-7.1M | ||
| Q2 25 | $-6.1M | $-12.4M | ||
| Q1 25 | $-2.0M | $-28.5M | ||
| Q4 24 | — | $-12.5M | ||
| Q3 24 | — | $-27.1M | ||
| Q2 24 | — | $-17.3M | ||
| Q1 24 | — | $-38.4M |
自由现金流ACOGADPT
| Q4 25 | $-7.1M | $1.4M | ||
| Q3 25 | $-5.4M | $-7.5M | ||
| Q2 25 | $-6.1M | $-13.1M | ||
| Q1 25 | $-2.1M | $-29.7M | ||
| Q4 24 | — | $-12.6M | ||
| Q3 24 | — | $-27.4M | ||
| Q2 24 | — | $-19.0M | ||
| Q1 24 | — | $-39.9M |
自由现金流率ACOGADPT
| Q4 25 | -252.6% | 2.0% | ||
| Q3 25 | -188.8% | -8.0% | ||
| Q2 25 | -370.9% | -22.2% | ||
| Q1 25 | -72.0% | -56.7% | ||
| Q4 24 | — | -26.5% | ||
| Q3 24 | — | -59.0% | ||
| Q2 24 | — | -44.1% | ||
| Q1 24 | — | -95.2% |
资本支出强度ACOGADPT
| Q4 25 | 5.3% | 0.9% | ||
| Q3 25 | 2.6% | 0.4% | ||
| Q2 25 | 0.5% | 1.1% | ||
| Q1 25 | 2.2% | 2.4% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 4.0% | ||
| Q1 24 | — | 3.6% |
现金转化率ACOGADPT
| Q4 25 | — | — | ||
| Q3 25 | — | -0.75× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACOG
暂无分部数据
ADPT
| Mrd Business Segment | $61.9M | 86% |
| Immune Medicine Business | $9.8M | 14% |
| Immune Medicine Service Revenue | $100.0K | 0% |
